# Kalion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kalion

- Industry: Chemicals
- Headquarters: US
- Website: www.kalioninc.com
- Total disclosed funding: $0.3M
- Latest round: Seed (Jan 1, 2014)
- Investors on record: 2

## About

Kalion, Inc. specializes in producing high-purity glucaric and glucuronic acids derived from biomass via advanced fermentation, serving diverse industries including pharmaceuticals and nutraceuticals.Kalion, Inc. is a biotechnology company founded in 2011 in the United States, focusing on the production of specialized biochemicals. The company has engaged in 4 funding deals, with the most recent deal occurring on February 25, 2019, where it raised USD 2.99 mn in venture funding from unspecified investors. Kalion operates from its headquarters in the US, reflecting its commitment to innovation in chemical production. The company’s founder has a history of involvement in similar ventures, contributing to its growth trajectory.Kalion, Inc. specializes in the production of high-purity glucaric acid and glucuronic acid derived from biomass through advanced fermentation methods. These chemicals serve critical roles in various industrial applications, such as enhancing mechanical properties of materials and preventing corrosion in water treatment systems. Glucaric acid is notably utilized in the pharmaceutical industry, including formulations like Adderall®, while both glucaric and glucuronic acids are also marketed as nutraceuticals. The company's proprietary synthetic biology techniques enable the creation of highly pure chemicals, positioning Kalion as a key supplier to sectors including pharmaceuticals, nutraceuticals, and industrial manufacturing. Kalion's products are distributed in multiple geographical markets, catering to diverse clients across North America, Europe, and Asia.Kalion, Inc. engages in business transactions primarily through B2B partnerships, supplying its high-purity chemicals to various manufacturers and industrial users. The company's revenue model is based on direct sales of its flagship products, including glucaric acid and glucuronic acid, tailored to meet the specific needs of its clients in the pharmaceutical and industrial sectors. Transactions typically involve negotiated contracts that detail product quantities, pricing structures, and delivery schedules, ensuring that clients receive consistent supplies of these specialized chemicals. Given the nature of the industry, Kalion structures its pricing to accommodate bulk orders and long-term agreements, fostering ongoing relationships with its customer base while supporting their specific applications in various sectors.Kalion, Inc. aims to expand its product line with new formulations of glucaric and glucuronic acids, targeting a release in the next two years. The company plans to penetrate new markets in Southeast Asia and South America by the end of 2024. The recent funding of USD 2.99 mn raised in February 2019 will be utilized to support these product development initiatives and market expansion efforts, enhancing its capacity to serve a broader customer base.

## Funding rounds

- Seed, Jan 1, 2014, $0.3M — Cherrystone Angel Group, Beta Fund

## Investors

- Cherrystone Angel Group (https://capitalatlas.ai/funds/cherrystone-angel-group) — Seed
- Beta Fund (https://capitalatlas.ai/funds/beta-fund) — Seed